Source Paper
Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients
Mateus M Bergamaschi, Regina Helena Costa Queiroz, Marcos Hortes Nisihara Chagas, Danielle Chaves Gomes de Oliveira, Bruno Spinosa De Martinis et al.
Neuropsychopharmacology • 2011
Simulated Public Speaking Test
Objective: Measure anxiety responses and cognitive/physiological changes during simulated public speaking performance in social anxiety disorder (SAD) patients and healthy controls
This is a Simulated Public Speaking Test protocol using human as the model organism. The procedure involves 5 procedural steps, 3 equipment items, 2 materials. Extracted from a 2011 paper published in Neuropsychopharmacology.
Model and subjects
human • 36
Study window
~1.5 hours hands-on
Core workflow
Subject allocation and randomization • Drug administration • Baseline measurements
Primary readouts
- Visual Analogue Mood Scale (VAMS) scores measuring anxiety, cognitive impairment, discomfort, and alert levels
- Negative Self-Statement scale (SSPS-N) scores measuring negative self-statements during speech
- Blood pressure (systolic and diastolic)
- Heart rate
Key equipment and reagents
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Subject allocation and randomization
Allocate 24 never-treated SAD patients to receive either CBD or placebo in a double-blind randomized design. Allocate 12 healthy controls to perform SPST without medication.
Note: Double-blind procedure maintained throughout
View evidence from paper
“24 never-treated patients with SAD were allocated to receive either CBD (600 mg; n=12) or placebo (placebo; n=12) in a double-blind randomized design”
Drug administration
Administer CBD (600 mg) or placebo to SAD patient groups
Note: Single dose administration
View evidence from paper
“CBD (600 mg; n=12) or placebo (placebo; n=12) in a double-blind randomized design 1 h and a half before the test”
Baseline measurements
Record baseline subjective ratings and physiological measures before SPST begins
Note: First of six measurement time points
View evidence from paper
“physiological measures (blood pressure, heart rate, and skin conductance) were measured at six different time points during the SPST”
Simulated public speaking test (SPST) performance
Each volunteer participates in one experimental session performing the SPST
Note: Each volunteer participated in only one experimental session in a double-blind procedure
View evidence from paper
“Each volunteer participated in only one experimental session in a double-blind procedure”
Repeated measurements during SPST
Measure subjective ratings on VAMS and SSPS-N scales and physiological measures (blood pressure, heart rate, skin conductance) at five additional time points throughout the test
Note: Measurements taken at regular intervals during SPST
View evidence from paper
“Subjective ratings on the Visual Analogue Mood Scale (VAMS) and Negative Self-Statement scale (SSPS-N) and physiological measures (blood pressure, heart rate, and skin conductance) were measured at six different time points during the SPST”